The virosomal influenza vaccine Invivac®:: Immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad®) in elderly subjects

被引：43

作者：

de Bruijn, I. A. ^{[1
]}

Nauta, J. ^{[1
]}

Gerez, L. ^{[1
]}

Palache, A. M. ^{[1
]}

机构：

[1] Solvay Pharmaceut BV, NL-1380 DA Weesp, Netherlands

来源：

VACCINE | 2006年 / 24卷 / 44-46期

关键词：

influenza; influenza vaccine; elderly; improved immunogenicity; tolerability; virosomal; adjuvant;

D O I：

10.1016/j.vaccine.2006.05.035

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Several approaches are currently being pursued in order to improve the efficacy of influenza vaccines in elderly individuals and others who have impaired immune responses to conventional influenza vaccines. There are two influenza vaccines available for elderly subjects: Fluad (R) (Chiron) and Invivac (R) (Solvay Pharmaceuticals). The present clinical study was a randomized, endpoint-blind, parallel group study in elderly subjects aged 61 years and older to investigate the safety and immunogenicity of these vaccines as compared to a standard influenza vaccine Invivac (R) (Solvay Pharmaceuticals). The three vaccines had similar immunogenicity results, whereas the tolerability profile of Invivac was better as compared to Fluad. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：6629 / 6631

页数：3